At the time of writing, Monte Rosa Therapeutics Inc [GLUE] stock is trading at $6.47, down -6.64%. An important factor to consider is whether the stock is rising or falling in short-term value. The GLUE shares have gain 33.95% over the last week, with a monthly amount glided 41.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monte Rosa Therapeutics Inc [NASDAQ: GLUE] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $11 from $14. Previously, Wedbush started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $11. On January 03, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $18 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $22 on October 13, 2022. Jefferies initiated its recommendation with a Buy and recommended $20 as its price target on August 15, 2022. Credit Suisse started tracking with a Neutral rating for this stock on April 28, 2022, and assigned it a price target of $19. In a note dated February 10, 2022, Wells Fargo initiated an Equal Weight rating and provided a target price of $19 on this stock.
For the past year, the stock price of Monte Rosa Therapeutics Inc fluctuated between $3.50 and $12.40. Monte Rosa Therapeutics Inc [NASDAQ: GLUE] shares were valued at $6.47 at the most recent close of the market.
Analyzing the GLUE fundamentals
According to Monte Rosa Therapeutics Inc [NASDAQ:GLUE], the company’s sales were 177.99M for trailing twelve months, which represents an 394.01% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.1 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Monte Rosa Therapeutics Inc [NASDAQ:GLUE] has a current ratio of 7.16. On the other hand, the Quick Ratio is 7.16, and the Cash Ratio is 1.66. Considering the valuation of this stock, the price to sales ratio is 2.24, the price to book ratio is 1.49 and price to earnings (TTM) ratio is 18.86.
Transactions by insiders
Recent insider trading involved Dunn Edmund, Principal Accounting Officer, that happened on Jun 03 ’25 when 2062.0 shares were sold. Director, Leo Chandra P. completed a deal on Mar 24 ’25 to buy 10000.0 shares. Meanwhile, 10% Owner Versant Venture Capital VI, L. sold 89990.0 shares on Oct 28 ’24.
